IDF Introduces New Guide to Hematopoietic Stem Cell Transplantation

Helping Parents and Patients Make Decisions

Whether you are recently facing a diagnosis of Chronic Granulomatous Disease (CGD) or been living with CGD for years, you have likely carefully considered the treatment options with your healthcare provider. Hematopoietic stem cell transplantation (HSCT) can be a consideration for treating CGD, depending on the assessment of an individual patient’s risks and benefits.

On one hand, patients with CGD can live full, active lives with prophylactic medication. They still, however, run the risk of serious infection. Meanwhile, HSCT carries serious risks, and the procedure requires several weeks or months in the hospital, followed by as much as a year to recover. Yet, if the transplant is successful, it can be a curative treatment for CGD.

To help parents and patients with CGD weigh the pros and cons of transplant as well as assess the options available, the Immune Deficiency Foundation (IDF) has developed the Guide to Hematopoietic Stem Cell Transplantation.

This guide includes approaches that could potentially benefit patients with several types of primary immunodeficiency diseases (PI), including CGD. Subsequent chapters provide more details as to how a patient is prepared for a transplant, what the transplant experience is like, and what life can be like after a transplant.

Click here to order or download the guide at no cost to you. 

As always, IDF is here for you. If you have any questions about HSCT or wish to discuss your options to manage or treat CGD, we are happy to connect you with the help you need. Click here to e-mail IDF.

Interested in hearing from experts on treatment options and connecting with others living with CGD? Join us at IDF Retreats this summer. Click here to learn more.

This content should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment are unique. The benefits and risks of any treatment should be discussed with the patient’s provider.

Posted in:

Leave a Reply